New dosing strategy aims to help breast cancer patients stick with treatment

NCT ID NCT07599137

Not yet recruiting Disease control Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether starting abemaciclib at a lower dose and gradually increasing it can reduce early side effects like diarrhea and fatigue in people with high-risk HR+/HER2- breast cancer. The goal is to help more patients stay on their full treatment plan. About 86 participants will be followed for 12 weeks to see how well they tolerate the step-up dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abemaciclib (a targeted cancer drug)
What this could lead to: If successful, this step-up dosing approach could help more patients tolerate and complete their full course of abemaciclib, potentially improving long-term outcomes.
What could go wrong: This is a small, early-phase study (86 participants) focused on tolerability, not on proving the drug works better. Side effects like diarrhea and fatigue may still occur, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+/HER2- BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR+/HER2- BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.